Navigation Links
Martek Wins German DHA Patent Infringement Actions Against Lonza and One of Nutrinova's Customers in Suits Relating to DHA Product Marketed for Use in Functional Foods and Dietary Supplements
Date:10/23/2007

COLUMBIA, Md., Oct. 23 /PRNewswire-FirstCall/ -- Martek Biosciences Corporation (Nasdaq: MATK) today announced that a three-judge panel of a district court in Dusseldorf, Germany, has orally announced a judgment in favor of Martek in the company's patent infringement suit against (i) Lonza Ltd., (ii) Celanese Ventures GmbH and (iii) Nutrinova Nutrition Specialties & Food Ingredients GmbH. In a separate suit against Lichtwer Pharma GmbH, one of Nutrinova's customers, a similar judgment was announced. The first suit involves Lonza's German sale and use of a fatty acid product currently marketed under the brand name Lonza DHA for use in functional foods and dietary supplements. The second suit involves Lichtwer's German sale and use of a DHA-containing oil in a supplement marketed under the brand name AMEU(R) Alge. The Martek patent that has been infringed is European Patent No. 0 515 460 relating to microbial oils containing at least 35% DHA (docosahexaenoic acid).

The court is expected to deliver its written judgments within thirty days. The decisions may be appealed by Lonza and Lichtwer to the higher regional court in Dusseldorf. The patent infringed by Lonza and Lichtwer has been the subject of opposition proceedings at the European Patent Office since 1999 and a final resolution of those proceedings is expected at some time in the second half of 2008. In October 2006, a jury in a U.S. federal district court in Delaware determined that Lonza's DHA activities in the functional food and dietary supplement areas infringed three U.S. Martek patents.

"We are very pleased that the court found that the actions of Lonza and Lichtwer infringe this European DHA patent of Martek. The decision further demonstrates both the company's resolve to vigorously defend its intellectual property portfolio and the strength of Martek's patent portfolio in the marketplace," said Steve Dubin, CEO of Martek.

About Martek Biosciences

Martek Biosciences Corporation (Nasdaq: MATK) is a leader in the innovation and development of DHA omega-3 products that promote health and wellness through every stage of life. The company produces life'sDHA(TM), a sustainable and vegetarian source of the omega-3 fatty acid DHA (docosahexaenoic acid), for use in foods, beverages, infant formula, and supplements. The company also produces life'sARA(TM) (arachidonic acid), an omega-6 fatty acid, from a sustainable, vegetarian source, for use in infant formula. For more information on Martek Biosciences Corporation, visit http://www.martek.com.

Forward-Looking Statements

Sections of this release contain forward-looking statements, including, without limitation, statements concerning the course and outcome of current and future legal proceedings and the strength of Martek's patent portfolio. These statements are based upon numerous assumptions which Martek cannot control and involve risks and uncertainties that could cause actual results to differ. For instance, Martek cannot predict with certainty any events associated with the litigation and appeal process, the future actions of Lonza or Lichtwer, the future actions of Martek's customers or prospective customers or the competitive and financial impact of any final court decision on the value of Martek's intellectual property. These statements should be understood in light of the risk factors set forth in the Company's filings with the Securities and Exchange Commission, including, but not limited to, the Company's Forms 8-K, 10-Q and 10-K.

CONTACT

Cassie France-Kelly

Public Relations

(443) 542-2116

cfrancekelly@martek.com

Kyle Stults

Investor Relations

(410) 740-0081

investors@martek.com


'/>"/>
SOURCE Martek Biosciences Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. German hospital established in Kashmir for earthquake relief
2. First Crossover Kidney Transplantation In Germany
3. Birds Flu Scare Reaches Germany
4. Karla: healthy beer as claimed by German manufacturers
5. Germany could start indoor poultry to avoid bird flu infection
6. MIOT Hospital Signs Agreement With German Healthcare Facility
7. German Nurse Makes A Confession
8. Indian Doctor Establishes His Name In Germany
9. Poultry Ordered Indoors Following Bird Flu Suspicion In Germany
10. New Bird Flu Cases In Germany Prompts Massive Culling Of Poultry
11. A warning and wake up call: German cat infected with deadly bird flu strain.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ... March 27, 2017 , ... Buzzies parent company, The ... for Rent the Runway Foundation and UBS’ Project Entrepreneur. Mayo will present her pitch ... 8. , Project Entrepreneur’s second annual venture competition ignites bold ideas by providing ...
(Date:3/27/2017)... ... March 27, 2017 , ... Osteitis ... A type of groin injury, it occurs when the muscles around the pelvis ... in and around the lower torso, as well as accompanying tenderness and weakness. ...
(Date:3/27/2017)... ... March 27, 2017 , ... The Association of Healthcare ... will hold their first Northeast Regional AHVAP Meeting. For 2017, Dr. Hayes will ... chain and value analysis professionals have a ‘seat at the table’ with clinical ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... announce the launch of a months-long rebranding effort. This includes the introduction of ... focus group discussions and market research, we learned that a simple, proactive approach ...
(Date:3/27/2017)... ... March 27, 2017 , ... Harris Communications, Inc., a leading provider ... its latest products to the Deaf Seniors of America Conference, April 4-7 at the ... meet with knowledgeable ASL friendly staff from Harris Communications and to try out the ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... 27, 2017 LightIntegra Technology Inc. today announced ... Dubiel as President and Chief Executive Officer effective March ... Board of Directors of LightIntegra. Paul Geyer ... LightIntegra. "This is the perfect time ... Executive Officer. We,ve selected a very strong leader at ...
(Date:3/27/2017)... 27, 2017  Sophiris Bio Inc. (NASDAQ: ... clinical late-stage biopharmaceutical company developing topsalysin (PRX302) for ... reported fourth quarter and full year 2016 financial ... Key Corporate Highlights: Advanced Topsalysin ... During 2016, the Company reported successful results with ...
(Date:3/27/2017)... Pulmatrix, Inc . (NASDAQ: PULM), a clinical stage biopharmaceutical company ... announced that it has added two experts in the fields ... Scientific Advisory Board . The two experts ... MD, former chief of the Pediatric Pulmonary and Allergy Divisions ... University, and David Denning , MD, ...
Breaking Medicine Technology: